In this Aug. 14, 2020, file photo, a street sweeper checks his mobile phone as he takes a break near a coronavirus-themed mural in Jakarta, Indonesia. The World Bank has approved $12 billion in financing to help developing countries buy and distribute coronavirus vaccines, tests, and treatments, aiming to support the vaccination of up to 1 billion people, the bank said in a statement late Tuesday, Oct. 13, 2020. (AP Photo/Tatan Syuflana, File)
The World Bank has approved $12 billion in financing to help developing countries buy and distribute coronavirus vaccines, tests, and treatments, aiming to support the vaccination of up to 1 billion people.
The $12 billion “envelope" is part of a wider World Bank Group package of up to $160 billion to help developing countries fight the COVID-19 pandemic, the bank said in a statement late Tuesday.
The World Bank said its COVID-19 emergency response programs are already reaching 111 countries.
Citizens in developing countries also need access to safe and effective COVID-19 vaccines, it said.
“We are extending and expanding our fast-track approach to address the COVID emergency so that developing countries have fair and equal access to vaccines,” said the bank's president, David Malpass, said in the statement.
“Access to safe and effective vaccines and strengthened delivery systems is key to alter the course of the pandemic and help countries experiencing catastrophic economic and fiscal impacts move toward a resilient recovery,” he said.
The International Finance Corporation, the private sector lending arm of the World Bank is investing in vaccine manufacturers through a $4 billion Global Health Platform, the World Bank said.
Researchers are working on developing more than 170 potential COVID-19 vaccines.
Development and deployment of such preventive vaccines is crucial to helping stem outbreaks of the coronavirus that has killed more than 1 million people and sickened more than 38 million, while devastating economies and leaving many millions jobless.
The world's richest countries have locked up most of the world's potential vaccine supply through 2021, raising worries that poor and vulnerable communities will not be able to get the shots. Meanwhile, an ambitious international project to deliver coronavirus vaccines to the world’s poorest people, called Covax, is facing potential shortages of money, cargo planes, refrigeration and vaccines themselves.
The World Bank said it will draw on expertise and experience from its involvement in many large-scale immunization programs and other public health efforts.
The funding also is meant to help countries access tests and treatments and to support management of supply chains and other logistics for vaccinations in developing countries, the bank said.
7 Best Stocks to Own Right Now
Today, we are inviting you to view our list of the seven best stocks to own for the next thirty days.
Why is it worth looking into these stocks? Some of Wall Street's most respected and most accurate research analysts have been upgrading these stocks and raising their price targets for these companies.
No, we're not talking recommendations from some no-name blogger or a junior analyst from a brokerage you've never heard of. These stocks have received multiple positive recommendations in the last 30 days from analysts that have received four star and five star rankings from MarketBeat's proprietary brokerage ranking system.
Analysts given four star and five star ratings from MarketBeat consistently issue accurate price targets and their buy recommendations often outperform the market by double digits. Buy recommendations from our current top-rated brokerage, National Securities, have gone up by an average of 47.5% in the 12 months after they were issued.
We've reviewed every research report published by these top-rated analysts in the last 90 days and have identified seven stocks that these analysts are poised for an immediate breakout.
View the "7 Best Stocks to Own Right Now".